FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes
The agency cleared the label on Aug. 28, 2026 after Lilly’s head‑to‑head SURPASS‑CVOT showed a modest cardiovascular advantage over Trulicity, a result that broadens Mounjaro’s clinical and commercial role.
